دورية أكاديمية
أعرض في EDS

WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2.

التفاصيل البيبلوغرافية
العنوان: WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2.
المؤلفون: Aragão LGHS; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Oliveira JT; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Temerozo JR; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Rio de Janeiro, Rio de Janeiro, Brazil.; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., Mendes MA; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Salerno JA; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Pedrosa CSG; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Puig-Pijuan T; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Veríssimo CP; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Ornelas IM; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Torquato T; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Vitória G; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Sacramento CQ; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., Fintelman-Rodrigues N; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., da Silva Gomes Dias S; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., Cardoso Soares V; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Souza LRQ; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Karmirian K; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Goto-Silva L; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Biagi D; Pluricell Biotech, São Paulo, São Paulo, Brazil., Cruvinel EM; Pluricell Biotech, São Paulo, São Paulo, Brazil., Dariolli R; Pluricell Biotech, São Paulo, São Paulo, Brazil.; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States., Furtado DR; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil., Bozza PT; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., Borges HL; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Souza TML; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil.; Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Rio de Janeiro, Brazil., Guimarães MZP; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil., Rehen SK; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Rio de Janeiro, Brazil.; Department of Genetics, Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Rio de Janeiro, Brazil.
المصدر: PeerJ [PeerJ] 2021 Oct 08; Vol. 9, pp. e12262. Date of Electronic Publication: 2021 Oct 08 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: PeerJ Inc Country of Publication: United States NLM ID: 101603425 Publication Model: eCollection Cited Medium: Print ISSN: 2167-8359 (Print) Linking ISSN: 21678359 NLM ISO Abbreviation: PeerJ Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Corte Madera, CA : PeerJ Inc.
مستخلص: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can infect several organs, especially impacting respiratory capacity. Among the extrapulmonary manifestations of COVID-19 is myocardial injury, which is associated with a high risk of mortality. Myocardial injury, caused directly or indirectly by SARS-CoV-2 infection, can be triggered by inflammatory processes that lead to damage to the heart tissue. Since one of the hallmarks of severe COVID-19 is the "cytokine storm", strategies to control inflammation caused by SARS-CoV-2 infection have been considered. Cannabinoids are known to have anti-inflammatory properties by negatively modulating the release of pro-inflammatory cytokines. Herein, we investigated the effects of the cannabinoid agonist WIN 55,212-2 (WIN) in human iPSC-derived cardiomyocytes (hiPSC-CMs) infected with SARS-CoV-2. WIN did not modify angiotensin-converting enzyme II protein levels, nor reduced viral infection and replication in hiPSC-CMs. On the other hand, WIN reduced the levels of interleukins six, eight, 18 and tumor necrosis factor-alpha (TNF-α) released by infected cells, and attenuated cytotoxic damage measured by the release of lactate dehydrogenase (LDH). Our findings suggest that cannabinoids should be further explored as a complementary therapeutic tool for reducing inflammation in COVID-19 patients.
Competing Interests: Diogo Biagi, Estela M. Cruvinel and Rafael Dariolli are employed by Pluricell Biotech.
(© 2021 Aragão et al.)
References: J Pharm Sci. 1967 Oct;56(10):1209-24. (PMID: 4861230)
Lancet. 2020 May 2;395(10234):1417-1418. (PMID: 32325026)
J Infect. 2020 Jul;81(1):147-178. (PMID: 32209382)
J Biol Chem. 2006 Oct 27;281(43):32879-90. (PMID: 16954222)
Sci Rep. 2019 Apr 15;9(1):6047. (PMID: 30988334)
Science. 2020 Mar 27;367(6485):1444-1448. (PMID: 32132184)
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. (PMID: 32233755)
Heart Fail Rev. 2011 Jan;16(1):49-69. (PMID: 20571888)
Aging (Albany NY). 2020 Nov 22;12(22):22425-22444. (PMID: 33221759)
Cells. 2021 Mar 24;10(4):. (PMID: 33805075)
N Engl J Med. 2020 Aug 6;383(6):590-592. (PMID: 32402155)
PLoS One. 2018 Dec 6;13(12):e0208321. (PMID: 30521586)
Cardiovasc Res. 2020 May 1;116(6):1097-1100. (PMID: 32227090)
Circ Res. 2020 May 8;126(10):1456-1474. (PMID: 32264791)
Int J Mol Sci. 2020 May 27;21(11):. (PMID: 32471272)
Sci Rep. 2021 Jan 14;11(1):1462. (PMID: 33446817)
Stem Cell Reports. 2019 Jun 11;12(6):1232-1241. (PMID: 31105048)
Sci Transl Med. 2021 Apr 21;13(590):. (PMID: 33723017)
Br J Pharmacol. 2007 Jun;151(4):427-40. (PMID: 17450170)
Cardiovasc Toxicol. 2016 Jul;16(3):244-50. (PMID: 26082188)
J Cannabis Res. 2020;2(1):23. (PMID: 32835160)
J Pharmacol Exp Ther. 1992 Dec;263(3):1118-26. (PMID: 1335057)
Lab Invest. 2016 Aug;96(8):839-52. (PMID: 27348628)
Mol Pharmacol. 1988 Nov;34(5):605-13. (PMID: 2848184)
Hippocampus. 2011 May;21(5):554-64. (PMID: 20135626)
Lancet Reg Health Am. 2021 Oct;2:100046. (PMID: 34485969)
Sci Adv. 2022 Feb 25;8(8):eabi6110. (PMID: 35050692)
Cell. 2020 Nov 25;183(5):1340-1353.e16. (PMID: 33096020)
Life Sci. 2020 Nov 1;260:118482. (PMID: 32971105)
Circulation. 2010 Aug 17;122(7):717-28, 18 p following 728. (PMID: 20679547)
J Biol Chem. 2008 Oct 24;283(43):29109-18. (PMID: 18701451)
J Med Virol. 2016 Jan;88(1):1-12. (PMID: 26059175)
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e246-e247. (PMID: 32294259)
Herz. 2020 Jun;45(4):321-322. (PMID: 32322935)
PeerJ. 2021 Dec 20;9:e12595. (PMID: 35036128)
Nature. 1993 Sep 2;365(6441):61-5. (PMID: 7689702)
SAGE Open Med. 2020 Oct 22;8:2050312120966456. (PMID: 33149912)
Pharmaceuticals (Basel). 2010 Jun 1;3(6):1873-1886. (PMID: 20634917)
Cardiovasc Res. 2010 Mar 1;85(4):773-84. (PMID: 19942623)
Mol Pharmacol. 1995 Sep;48(3):443-50. (PMID: 7565624)
J Pharmacol Exp Ther. 1994 Dec;271(3):1383-90. (PMID: 7996450)
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285. (PMID: 32730555)
Front Physiol. 2021 Feb 17;12:624185. (PMID: 33679437)
Circulation. 1995 Mar 1;91(5):1520-4. (PMID: 7867193)
Br J Pharmacol. 2019 Dec;176(24):4653-4665. (PMID: 31412133)
Cell Rep Med. 2020 Jul 21;1(4):100052. (PMID: 32835305)
FASEB J. 2011 Jul;25(7):2500-8. (PMID: 21478262)
Cytokine. 2002 May 21;18(4):199-205. (PMID: 12126642)
Stem Cell Res Ther. 2020 Nov 30;11(1):514. (PMID: 33256833)
Nat Rev Cardiol. 2018 Mar;15(3):151-166. (PMID: 28905873)
JAMA Dermatol. 2020 Jul 1;156(7):820-822. (PMID: 32352487)
PLoS One. 2015 Apr 13;10(4):e0122843. (PMID: 25874692)
Biology (Basel). 2020 Nov 05;9(11):. (PMID: 33167441)
Mol Cell Biochem. 2006 Feb;283(1-2):75-83. (PMID: 16444588)
PLoS One. 2007 Jul 25;2(7):e641. (PMID: 17653268)
Cytokine Growth Factor Rev. 2020 Jun;53:25-32. (PMID: 32446778)
Exp Physiol. 2005 Sep;90(5):783-90. (PMID: 16049057)
Nat Commun. 2020 Jul 30;11(1):3810. (PMID: 32733001)
Lancet Child Adolesc Health. 2020 Oct;4(10):790-794. (PMID: 32828177)
World J Gastroenterol. 2016 Nov 21;22(43):9515-9524. (PMID: 27920472)
Neurosci Lett. 2011 Jan 10;487(3):411-4. (PMID: 21055447)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Neuroscience. 2007 Feb 23;144(4):1516-22. (PMID: 17178196)
Rev Neurol. 2020 May 1;70(9):311-322. (PMID: 32329044)
Nat Commun. 2017 Jan 03;8:13958. (PMID: 28045021)
Eur Heart J. 2020 May 14;41(19):1807-1809. (PMID: 32383758)
J Leukoc Biol. 2013 May;93(5):801-10. (PMID: 23463725)
Nat Rev Cardiol. 2020 May;17(5):259-260. (PMID: 32139904)
J Pharmacol Exp Ther. 2000 Apr;293(1):136-50. (PMID: 10734163)
Circ J. 2020 Oct 23;84(11):2027-2031. (PMID: 32981925)
فهرسة مساهمة: Keywords: COVID-19; Cannabinoids; Human iPSC-derived cardiomyocytes; SARS-Cov-2; WIN 55,212-2
تواريخ الأحداث: Date Created: 20211028 Latest Revision: 20240403
رمز التحديث: 20240403
مُعرف محوري في PubMed: PMC8504461
DOI: 10.7717/peerj.12262
PMID: 34707939
قاعدة البيانات: MEDLINE
الوصف
تدمد:2167-8359
DOI:10.7717/peerj.12262